Aragen Life Sciences files a draft red herring prospectus (DRHP) with India’s market regulator SEBI for an initial public offering (IPO). Multiple outlets report that the planned transaction includes a fresh issue of ₹800 crore.
According to NDTV, the IPO’s book-running lead managers include Axis Capital, Citigroup Global Markets India, Goldman Sachs (India) Securities and JM Financial. The Hindu adds that, beyond the ₹800 crore fresh issue, the offering also includes an offer for sale (OFS) of up to 27,329,192 equity shares. Times of India also reports the ₹800 crore figure for the fresh component, aligning with the other coverage, though it offers less detail on the OFS structure.
Overall, the outlets agree on the core elements: the DRHP filing with SEBI and the IPO’s proposed ₹800 crore fresh issue, with The Hindu specifying an additional OFS portion and NDTV listing the lead managers.
